SCYNEXIS (SCYX) & Karyopharm Therapeutics (KPTI) Head to Head Contrast

SCYNEXIS (NASDAQ: SCYX) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, earnings, risk, valuation, institutional ownership and profitabiliy.

Risk & Volatility

SCYNEXIS has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 4.25, meaning that its share price is 325% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for SCYNEXIS and Karyopharm Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SCYNEXIS 0 1 5 1 3.00
Karyopharm Therapeutics 0 0 7 0 3.00

SCYNEXIS currently has a consensus price target of $11.57, indicating a potential upside of 605.57%. Karyopharm Therapeutics has a consensus price target of $15.44, indicating a potential upside of 70.09%. Given SCYNEXIS’s higher probable upside, research analysts clearly believe SCYNEXIS is more favorable than Karyopharm Therapeutics.

Profitability

This table compares SCYNEXIS and Karyopharm Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SCYNEXIS -11,148.09% -69.47% -43.72%
Karyopharm Therapeutics -50,646.40% -72.41% -65.15%

Earnings and Valuation

This table compares SCYNEXIS and Karyopharm Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
SCYNEXIS $256,999.00 164.63 -$26.60 million N/A N/A
Karyopharm Therapeutics $222,000.00 1,927.17 -$112.94 million ($2.89) -3.14

SCYNEXIS has higher revenue and earnings than Karyopharm Therapeutics.

Insider & Institutional Ownership

46.2% of SCYNEXIS shares are owned by institutional investors. Comparatively, 57.1% of Karyopharm Therapeutics shares are owned by institutional investors. 3.9% of SCYNEXIS shares are owned by insiders. Comparatively, 14.8% of Karyopharm Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

SCYNEXIS beats Karyopharm Therapeutics on 7 of the 12 factors compared between the two stocks.

About SCYNEXIS

SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. The Company’s lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. It is also engaged in the clinical development of selinexor in various solid tumor indications. Oral selinexor is being evaluated in multiple later-phase clinical trials in patients with relapsed and/or refractory hematological and solid tumor malignancies. Its lead drug candidate, oral selinexor (KPT-330), as well as verdinexor (KPT-335), KPT-8602 and KPT-9274 are in clinical development.

Receive News & Ratings for SCYNEXIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.